Cardlytics (NASDAQ:CDLX) Stock Rating Upgraded by Wall Street Zen

Cardlytics (NASDAQ:CDLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research firms also recently issued reports on CDLX. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Cardlytics in a report on Wednesday, July 8th. Finally, Lake Street Capital set a $10.00 target price on shares of Cardlytics in a research report on Friday, May 8th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Sell” and an average target price of $10.00.

Cardlytics Price Performance

CDLX stock opened at $3.65 on Friday. The stock has a market capitalization of $21.21 million, a P/E ratio of -0.20 and a beta of 0.62. Cardlytics has a fifty-two week low of $3.49 and a fifty-two week high of $32.80. The business has a 50-day moving average of $4.63 and a 200-day moving average of $7.36.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.30) by $0.80. The business had revenue of $36.88 million for the quarter, compared to analyst estimates of $37.00 million. Cardlytics had a negative return on equity of 956.56% and a negative net margin of 55.92%. Equities analysts expect that Cardlytics will post -1.1 EPS for the current year.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 9,640 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $4.39, for a total value of $42,319.60. Following the completion of the sale, the chief executive officer owned 113,850 shares in the company, valued at $499,801.50. This trade represents a 7.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO David Thomas Evans acquired 15,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $6.50 per share, with a total value of $97,500.00. Following the transaction, the chief financial officer owned 26,793 shares in the company, valued at approximately $174,154.50. This trade represents a 127.19% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have sold 18,289 shares of company stock worth $80,289. 5.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cardlytics

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE lifted its position in shares of Cardlytics by 262.7% in the third quarter. Bank of America Corp DE now owns 1,632,786 shares of the company’s stock valued at $3,968,000 after buying an additional 1,182,593 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Cardlytics by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 654,472 shares of the company’s stock valued at $753,000 after purchasing an additional 20,908 shares during the last quarter. UBS Group AG boosted its position in Cardlytics by 112.5% during the third quarter. UBS Group AG now owns 458,066 shares of the company’s stock worth $1,113,000 after purchasing an additional 242,536 shares during the period. Invesco Ltd. boosted its position in Cardlytics by 38.1% during the fourth quarter. Invesco Ltd. now owns 170,122 shares of the company’s stock worth $196,000 after purchasing an additional 46,973 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of Cardlytics by 263.0% in the second quarter. Jane Street Group LLC now owns 162,427 shares of the company’s stock valued at $267,000 after purchasing an additional 117,687 shares during the last quarter. 68.10% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.